Socio-demographic characteristics, features of the course and treatment of ulcerative colitis in the Nizhny Novgorod region

Author:

Zlobin M. V.1ORCID,Alekseeva A. A.1ORCID,Kolodey E. N.1ORCID,Alekseeva O. P.1ORCID

Affiliation:

1. Nizhny Novgorod N. A. Semashko Regional Clinical Hospital

Abstract

The aim of the study was to describe the socio-demographic characteristics, features of the course and treatment of patients with ulcerative colitis. From March 2019 to March 2021, information was collected and systematized on patients over 18 years old in the Nizhny Novgorod region suffering from IBD. The registry included and analyzed 150 unique records of patients with ulcerative colitis. According to the analysis, the number of men and women with ulcerative colitis is comparable: men - 47.3% and 52.7%. The median age of all patients was 43.0 [19.0-83.0] years. Determination of a subjective assessment of the time of onset of the first symptoms found that the median age is 37.0 [14.7-83.2] years. The median duration of the disease at the time of inclusion in the study was 26.1 [3.4; 104.5] month. During the first year, it is possible to detect pathology in 85.3% of cases: for a period of less than 3 months in 63.3% of patients, within 3 to 6 months in 16.0%, in the period from 6- up to 12 months in 6.0%. Among the examined patients, the prevalence of total colitis was established - 54.6%; in second place - the leftside colitis - 34.0%, the least common was proctitis - 11.3%. According to our data, the “average patient” will be a woman or a man of average working age who seeks medical help in a timely manner, which allows a diagnosis to be made within the first 3 months from the onset of the first symptoms; however, despite such an optimistic start, in the vast majority of cases there is a total colitis and there is no adequate control over the disease - high activity of the disease (moderate attack) and a chronic recurrent course remain, which in turn leads to the appointment of repeated courses of corticosteroids and only in a quarter of cases, therapy is changed to genetically engineered biological agents.

Publisher

LLC Global Media Technology

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. Ng, S.C., Shi, H.Y., Hamidi N., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0.

2. Knyazev O. V., Belousova E. A., Abdulganieva D. I., et al. Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study. Almanac of Clinical Medicine. 2021;49(7):443-454. (in Russ.) doi: 10.18786/2072-0505-2021-49-061@@ Knyazev O. V., Belousova E. A., Abdulganieva D. I. i dr. Real'naya praktika lekarstvennoi terapii srednetyazhelykh i tyazhelykh form vospalitel'nykh zabolevanii kishechnika v Rossii, Respublike Belarus' i Respublike Kazakhstan. Promezhutochnye rezul'taty issledovaniya INTENT. Al'manakh klinicheskoi meditsiny. 2021;49(7):443-454. doi: 10.18786/2072-0505-2021-49-061.

3. Available at: https://ueg.eu/p/61#whitebhttps://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/alcoholspecificdeathsintheuk/2021registrationsook. Access 27.01.2023.

4. Targownik, L.E., Kaplan, G.G., Witt, J., et al. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. Am. J. Gastroenterol. 2020, 115, 128-137. doi: 10.14309/ajg.0000000000000503.

5. Burisch, J., Vardi, H., Schwartz, D., et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: A population-based study. Lancet Gastroenterol. Hepatol. 2020 May;5(5):454-464. doi: 10.1016/S2468-1253(20)30012-1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3